Skip to main content
Equibles
MDGL logo

MDGL · Madrigal Pharmaceuticals, Inc.

Track MDGL — free

Use MDGL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about MDGL

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$507.56 +0.19 (+0.04%) At close · Aug 14
Market Cap
$11.73B
Shares
23.10M

Madrigal Pharmaceuticals, Inc. Earnings Call Transcripts

Every quarterly earnings call for Madrigal Pharmaceuticals, Inc. (MDGL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$63.10M '21 Q3 21-11-04 · $ −$57.52M '22 Q1 22-05-09 · $ −$147.54M '24 Q1 24-05-07 · $14.64M −$151.97M '24 Q2 24-08-07 · $62.17M −$106.96M '24 Q3 24-10-31 · $103.32M −$59.42M '24 Q4 25-02-26 · $137.25M −$73.24M '25 Q1 25-05-01 ▲1353.8% $212.80M −$42.28M '25 Q2 25-08-05 ▲362% $287.27M −$114.19M '25 Q3 25-11-04 ▲210.8% $321.08M −$58.58M '25 Q4 26-02-19 ▲126.8% $311.34M −$94.39M '26 Q1 26-05-06 LATEST ▲71.2% $364.25M −$57.94M '26 Q2 26-07-30
Conference
Investor event
2026-08-11
Canaccord Genuity 46th Annual Growth Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-30
Q2 2026 Earnings Call
Confident tone ResDifera Commercial Performance MASH Market Expansion Intellectual Property / Patent Estate
Revenue
$364.25M
▲ 71.2% YoY
Diluted EPS
$-1.99
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-10
47th Annual Global Goldman Sachs Health Care Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Madrigal Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone F4C compensated cirrhosis indication expansion MASH market opportunity and expansion Path to peak sales and long-term outlook
Revenue
$311.34M
▲ 126.8% YoY
Diluted EPS
$-3.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-03
TD Cowen 46th Annual Health Care Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-19
Madrigal Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone Rezdiffra launch and net sales performance F4C (compensated NASH cirrhosis) opportunity Patent exclusivity
Revenue
$321.08M*
▲ 210.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Madrigal Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone Rezdiffra launch performance Pipeline and MAESTRO-NASH Gross to net dynamics
Revenue
$287.27M
▲ 362% YoY
Diluted EPS
$-4.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Madrigal Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone Rezdiffra launch performance F4c compensated MASH cirrhosis / OUTCOMES trial Oral GLP-1 business development (MGL-2086)
Revenue
$212.80M
▲ 1353.8% YoY
Diluted EPS
$-1.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Madrigal Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Revenue
$137.25M
Diluted EPS
$-2.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Madrigal Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone U.S. Rezdiffra Launch Execution Market Penetration & Growth Opportunity F4c Cirrhosis Data & Label Expansion
Revenue
$103.32M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Madrigal Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone Rezdiffra US launch performance Pipeline and long-term leadership in NASH Business development and pipeline expansion
Revenue
$62.17M
Diluted EPS
$-4.92
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Madrigal Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone Patient education and disease awareness Rezdiffra launch metrics Wiring the system / physician activation
Revenue
$14.64M
Diluted EPS
$-7.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Madrigal Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone Rezdiffra U.S. launch progress Clinical pipeline expansion Patient access and reimbursement
Revenue
$
Diluted EPS
$-7.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Madrigal Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Revenue
$
Diluted EPS
$-3.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q3
2021-11-04
Madrigal Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$
Diluted EPS
$-3.79
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–15 of 15 earnings calls
Key facts CIK 1157601 CUSIP 558868105 13F (30d) 386 filings 383 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)